Advertisement

Picture [iito] Life Science Business Portals Media Data 2022 2 650x100px
Document › Details

Celeris Therapeutics GmbH. (2/2/22). "Press Release: Celeris Therapeutics, the PIC Engineering Company, Announces the Appointment of Biotech Veterans to Lead Drug Discovery and Biology Efforts".

Organisations Organisation Celeris Therapeutics GmbH
  Group Celeris Therapeutics (CelerixTx) (Group)
  Organisation 2 PhoreMost Ltd.
Products Product proximity-inducing compounds (PIC™ degrader drugs)
  Product 2 Celeris One™ platform
Persons Person Kroll, Friedrich (Celeris Therapeutics 202202– VP of Drug Discovery)
  Person 2 Müllner, Markus (Celeris Therapeutics 202202– VP of Biology before PhoreMost)
     


The hirings of Dr. Friedrich Kroll, who is joining as VP of Drug Discovery, and Dr. Markus Muellner joining as VP of Biology, reflect the ambition to get into the clinic fast.

Dr. Friedrich Kroll, who has more than 25 years of experience in medicinal and computational chemistry, obtained his PhD back in 1992 at the Marburg University in organic chemistry and worked with several big pharma and biotech companies, leading teams of up to 40 people. His vast experience covers all stages in drug development, and his prior work led to drugs on the market.

"I am delighted to lead Celeris Therapeutics' drug discovery programs focused on CNS and oncology based on the Celeris One™ platform and a strong team. I am very excited about the progress to come.", stated Dr. Friedrich Kroll, the new VP of Drug Discovery at Celeris Therapeutics.

Dr. Markus Muellner moved from academia to biotech following several high-impact publications on cancer vulnerabilities, eventually joining the leadership team at PhoreMost Ltd. in Cambridge, UK, as CTO. At Celeris Therapeutics, he oversees the dry and wet labs, drug discovery programs, and robotized wet-lab efforts that are part of the Celeris One™ platform.

"I am very excited to build on the successes to date and continue the development of the internal drug pipeline while we successively implement the vision of our automated platform.", commented Dr. Markus Muellner, the new VP of Biology at Celeris Therapeutics.

"The addition of two such experienced and outstanding leaders to our executive team is a significant milestone. Their support is critical and will contribute substantially to our progress in drug and platform development.", says Christopher Trummer, CEO and Co-Founder of Celeris Therapeutics.


About Celeris Therapeutics

Celeris Therapeutics is an AI-first drug development company that uses innovative, computer-driven methods to develop PIC™ degrader drugs for yet-to-be drugged pathogenic proteins related to Parkinson's and various types of cancers.

Celeris Therapeutics' technical solution is the platform Celeris One™. Celeris Therapeutics collaborates with pharma and biotech companies to co-develop drugs in areas of high unmet medical need and develops wholly-owned drug programs.

Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.

To learn more, vis­it www.celeristx.com

   
Record changed: 2022-03-10

Advertisement

Picture [iito] Made Without Love 650x100px

More documents for Celeris Therapeutics (CelerixTx) (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top